Insider buying last 90 days
No open-market insider purchases were filed for IOVA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Iovance's week centers on record third-quarter results and renewed analyst confidence. The company reported Q3 2026 revenue of $122 million, an 80% year-over-year increase, with Amtagvi sales surpassing $100 million for the first time. Iovance reaffirmed its 2026 revenue guidance of $410 million to $420 million and pointed to cash resources lasting into 2029. Following the print, Citizens maintained its Market Outperform rating and raised its price target to $12 from $8.
The stock closed at $8.17, up 1.6%, sitting between its 50-day average of $11.38 and 200-day average of $6.01, reflecting a mixed trend picture. The GekkoIndex reads 67.6, placing it in the Accumulation zone, though the reading has slipped 3.3 points over the past five sessions. Price remains 14.5% below Gekko Fair Value of $9.56.
The next earnings date falls on 23 February 2027, 105 days out, placing it beyond a typical 20-trading-day swing window. Options activity shows 2 unusual signals over the past 30 days, with put premium of $401,542 exceeding call premium of $222,972. Seasonality data over 5 years shows the next 20 trading days averaging -2.9%, with gains in 2 of those years. Analyst coverage stands at 8 buy and 2 hold ratings among 10 firms, with a consensus target of $14.30.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Iovance Biotherapeutics scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
Averages disagree
Close $7.76 sits between the 50-day ($11.33) and 200-day ($6.11) averages, or the averages disagree.
See the chart67.3, Accumulation
Reading 67.3 is in the Accumulation zone.
See the GekkoIndex18.8% below
Price is 18.8% below Gekko Fair Value (more than 5% below).
See fair valueLeans bearish
Last 30 days: 2 unusual options signals.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings+2.9% on average
From this point in the calendar, the next 20 trading days averaged +2.9% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Iovance Biotherapeutics closed at $7.76 on Nov 13, 2026, +205.5% over the past year, inside a 52-week range of $2.08 to $15.37.
Use the left and right arrow keys to read daily values.
Put IOVA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Iovance Biotherapeutics develops experimental cancer treatments built around harnessing a patient's own immune defenses to fight tumors from within. The company has not yet reached commercial sales, remaining in clinical development, and its research is anchored by a lead candidate called lifileucel, which is being studied in people with advanced melanoma as well as those facing cervical cancer that has returned, spread, or persisted after other treatment. A second compound, LN-145, is being tested in patients dealing with head and neck squamous cell carcinoma that has come back or spread, and altogether the company has six separate Phase 2 studies underway.
Rather than earning revenue from finished products, Iovance advances its pipeline through collaborations and licensing deals with outside research and treatment centers. Its partners include Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG, reflecting a reliance on shared scientific and clinical resources rather than a customer base in the traditional sense.
The company traces back to 2007 and operated for years under the name Lion Biotechnologies before switching to its current identity in June 2017. It runs its operations from San Carlos, California, and its shares trade on the NASDAQ under the ticker IOVA.
Iovance Biotherapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.3, in the Accumulation zone, down 1.3 points over five sessions.
Down 1.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 82 | +1.6% | +3.9% |
| Accumulation (current zone) | 224 | +1.9% | +3.9% |
| Neutral | 347 | +0.5% | +7.4% |
| Distribution | 37 | +2.9% | +2.0% |
| Selling | 12 | −1.3% | −13.8% |
Average IOVA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Iovance Biotherapeutics trades 18.8% below Gekko Fair Value of $9.56, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Iovance Biotherapeutics shares are worth, recalculated every trading day.
$9.56
Gekko Fair Value, Nov 14, 2026
18.8% Undervalued
At the end of Aug 2026 the price was 23.0% above the estimate.
No open-market insider purchases were filed for Iovance Biotherapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for IOVA in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in IOVA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Iovance Biotherapeutics has been buying back its own shares.
From company filings.
2signals, 36% of the flagged premium in calls.
Latest: Bearish flow on Oct 22, $369K in unusual premium.
0of the funds Gekko tracks hold IOVA.
Iovance Biotherapeutics reports on Feb 23, 2027 (100 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 23, 2027
100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 5, 2026 | −$0.05 est −$0.08 | $121.5M est $116.0M | −7.6% |
| Aug 6, 2026 | −$0.11 est −$0.17 | $99.31M est $87.83M | +46.1% |
| May 7, 2026 | −$0.19 est −$0.15 | $71.43M est $77.84M | −11.5% |
| Feb 24, 2026 | −$0.18 est −$0.18 | $86.71M est $80.71M | +32.5% |
| Nov 6, 2025 | −$0.25 est −$0.26 | $67.46M est $82.17M | +27.1% |
| Aug 7, 2025 | −$0.33 est −$0.29 | $59.95M est $78.32M | −18.2% |
| May 8, 2025 | −$0.36 est −$0.25 | $49.32M est $82.37M | −44.1% |
| Feb 27, 2025 | −$0.26 est −$0.27 | $73.69M est $72.17M | −20.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Iovance Biotherapeutics is $14.50, +86.9% from the last close, from 10 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 10 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | H.C. Wainwright | $20 | +157.7% |
| Nov 6 | Barclays | $19 | +144.8% |
| Nov 6 | Citizens JMP | $12 | +54.6% |
| Nov 5 | H.C. Wainwright | $20 | +157.7% |
| Nov 3 | UBS | $8 | +3.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Iovance Biotherapeutics averaged +2.9% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −5.9% | 1 of 5 |
| Next 10 trading days | −1.6% | 2 of 5 |
| Next 15 trading days | +3.9% | 2 of 5 |
| Next 20 trading days | +2.9% | 1 of 5 |
| Next 30 trading days | +10.0% | 2 of 5 |
For scale, IOVA’s typical 20-trading-day move in either direction is about 14.8%.
Iovance Biotherapeutics’s market cap is $3.59B and revenue of $379.0M over the last twelve months.
Coverage of Iovance Biotherapeutics this week reads positive: 6 positive, 3 neutral and 1 negative headlines.
Iovance Biotherapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Iovance Biotherapeutics’s market cap is $3.59B at the Nov 13, 2026 close of $7.76, with 462.7M shares outstanding.
The consensus analyst 12-month price target for Iovance Biotherapeutics is $14.50, +86.9% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Iovance Biotherapeutics is undervalued: the Nov 13, 2026 close of $7.76 is 18.8% below Gekko Fair Value of $9.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Iovance Biotherapeutics is expected to report on Feb 23, 2027 (100 days away). Analysts expect earnings of −$0.07 per share on revenue of $128.6M. Iovance Biotherapeutics beat the earnings estimate in 4 of its last 8 reports, moving 26% on average across the report.
Iovance Biotherapeutics’s 52-week high is $15.37 and its 52-week low is $2.08; it closed at $7.76 on Nov 13, 2026, +205.5% over the past year. Over the last five years the shares peaked at $21.18 on Nov 15, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (trend and seasonality) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in Iovance Biotherapeutics over the last 30 days, with $223K of flagged premium in calls and $402K in puts. The latest, bearish flow, was on Oct 22, 2026 with $369K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.